Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO)
CUSIP: 87975F104
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, no par value
- Shares outstanding
- 34,382,284
- Total 13F shares
- 2,332,205
- Share change
- -474,330
- Total reported value
- $3,240,559
- Price per share
- $1.39
- Number of holders
- 31
- Value change
- -$616,944
- Number of buys
- 13
- Number of sells
- 30
Quarterly Holders Quick Answers
What is CUSIP 87975F104?
CUSIP 87975F104 identifies TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 87975F104:
Top shareholders of TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Bay Shore Trust |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
5,631,721
mixed-class rows
|
$20,414,715 | — | 21 Nov 2024 | |
| Christopher Chapman MD |
3/4/5
|
CEO & Chairman, Director |
—
class O/S missing
|
975,610
|
$6,048,782 | — | 08 Feb 2024 | |
| MIRA PHARMACEUTICALS, INC. |
3/4/5
|
10%+ Owner |
10%
|
3,521,127
|
$4,823,943 | — | 29 Sep 2025 | |
| Craig Eagle |
3/4/5
|
Director |
—
class O/S missing
|
487,805
|
$3,024,391 | — | 08 Feb 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.3%
|
1,118,226
|
$1,397,783 | — | 30 Jun 2025 | |
| Nathen Fuentes |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
101,134
|
$627,031 | — | 08 Feb 2024 | |
| BlackRock, Inc. |
13F
|
Company |
1.1%
|
370,076
|
$462,595 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.72%
|
247,699
|
$309,624 | — | 30 Jun 2025 | |
| Bradley Kroenig |
3/4/5
|
Director |
—
class O/S missing
|
48,781
|
$302,442 | — | 08 Feb 2024 | |
| Hugh Mccoll III |
3/4/5
|
Director |
—
class O/S missing
|
48,781
|
$302,442 | — | 08 Feb 2024 | |
| Talhia Tuck |
3/4/5
|
Director |
—
class O/S missing
|
48,781
|
$302,442 | — | 08 Feb 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.57%
|
196,880
|
$246,227 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.47%
|
160,594
|
$200,743 | — | 30 Jun 2025 | |
| Michelle Yanez |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
224,391
mixed-class rows
|
$151,224 | — | 27 Aug 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.22%
|
75,770
|
$94,713 | — | 30 Jun 2025 | |
| Y-Intercept (Hong Kong) Ltd |
13F
|
Company |
0.19%
|
64,423
|
$80,529 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.18%
|
61,600
|
$77,000 | — | 30 Jun 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.15%
|
51,453
|
$64,316 | — | 30 Jun 2025 | |
| Suncoast Equity Management |
13F
|
Company |
0.15%
|
51,194
|
$63,993 | — | 30 Jun 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.14%
|
49,556
|
$61,945 | — | 30 Jun 2025 | |
| UBS Group AG |
13F
|
Company |
0.14%
|
48,731
|
$60,914 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.12%
|
41,844
|
$52,305 | — | 30 Jun 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.1%
|
33,234
|
$41,543 | — | 30 Jun 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.08%
|
28,889
|
$36,000 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.08%
|
26,509
|
$33,136 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.07%
|
25,407
|
$31,759 | — | 30 Jun 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.07%
|
23,817
|
$29,771 | — | 30 Jun 2025 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
0.07%
|
22,911
|
$28,639 | — | 30 Jun 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.06%
|
20,960
|
$26,198 | — | 30 Jun 2025 | |
| Jain Global LLC |
13F
|
Company |
0.05%
|
16,399
|
$20,499 | — | 30 Jun 2025 | |
| OneDigital Investment Advisors LLC |
13F
|
Company |
0.04%
|
14,000
|
$17,500 | — | 30 Jun 2025 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.03%
|
10,829
|
$13,536 | — | 30 Jun 2025 | |
| Tactive Advisors, LLC |
13F
|
Company |
0.03%
|
10,000
|
$12,500 | — | 30 Jun 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.03%
|
8,646
|
$10,808 | — | 30 Jun 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.02%
|
7,443
|
$9,304 | — | 30 Jun 2025 | |
| FMR LLC |
13F
|
Company |
0.02%
|
5,605
|
$7,006 | — | 30 Jun 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.01%
|
3,017
|
$3,772 | — | 30 Jun 2025 | |
| CWM, LLC |
13F
|
Company |
0.01%
|
2,707
|
$3,000 | — | 30 Jun 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.01%
|
2,075
|
$2,594 | — | 30 Jun 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.01%
|
1,793
|
$2,241 | — | 30 Jun 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.01%
|
1,762
|
$2,203 | — | 30 Jun 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
1,261
|
$1,576 | — | 30 Jun 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
562
|
$1,000 | — | 30 Jun 2025 | |
| JONES FINANCIAL COMPANIES LLLP |
13F
|
Company |
0%
|
600
|
$918 | — | 30 Jun 2025 | |
| Fortitude Family Office, LLC |
13F
|
Company |
0%
|
667
|
$834 | — | 30 Jun 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
149
|
$186 | — | 30 Jun 2025 | |
| NISA INVESTMENT ADVISORS, LLC |
13F
|
Company |
0%
|
96
|
$120 | — | 30 Jun 2025 | |
| EverSource Wealth Advisors, LLC |
13F
|
Company |
0%
|
46
|
$58 | — | 30 Jun 2025 | |
| Allworth Financial LP |
13F
|
Company |
0%
|
12
|
$15 | — | 30 Jun 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
4
|
$5 | — | 30 Jun 2025 |
Institutional Holders of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) as of Q3 2025
As of 30 Sep 2025,
Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,332,205 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., MILLENNIUM MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, RAYMOND JAMES FINANCIAL INC, UBS Group AG, STATE STREET CORP, Bank of New York Mellon Corp, Suncoast Equity Management, and NORTHERN TRUST CORP.
This page lists
31
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
42
Q3 2025 holders
31
Holder diff
-11
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.